The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2022 | KEYNOTE-061: association between gene expression signatures & outcomes
Kohei Shitara, National Cancer Center Hospital East, Kashiwa, Japan discusses the association between gene expression signatures and outcomes of pembrolizumab and paclitaxel, in patients with advanced gastric or gastro-esophageal cancer with high PD-1 level expression. The gene expression profile (GEP) showed some association with clinical outcomes of pembrolizumab but not paclitaxel. Dr Shitara also talks about the negative associations for each drug and suggests that myeloid-driven suppression could be influential in the resistance to PD-1 inhibition. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
